Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cells

被引:58
|
作者
Rajgolikar, G
Chan, KK
Wang, HCR
机构
[1] Univ Tennessee, Coll Vet Med, Dept Comparat Med, Knoxville, TN 37996 USA
[2] Ohio State Univ, Ctr Comprehens Canc, Dev Therapeut Program, Columbus, OH 43210 USA
关键词
anticancer agent; apoptosis; breast cancer cells; FR901228; intracellular signaling pathways;
D O I
10.1023/A:1006091014092
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Human breast cancer MCF7 and MDA-MB231 cells were used to investigate the biological and molecular activities of a novel naturally occurring agent, FK901228 (FK), that possesses a potent antitumor activity against hum an and murine tumor cells. Investigation of the cytotoxicity of FR and induction of internucleosomal DNA degradation in FR-treated cultures revealed that FR induced apoptotic-like cell death of MCF7 and MDA-MB231 cells. In FR-treated apoptotic cultures, flow cytometry? revealed that there was a significant decrease of cells in S phase of the cell cycle. In FK-treated ce Ils there was an increased expression of p21(Cip1) and phosphorylation of Bcl-2 as determined by Western immunoblotting, and a novel cytoplasmic kinase of 33 kDa, p33 kinase, as determined by the in-gel kinase assay using myelin basic protein (MBP) as a substrate. Increased expression of P21(Cip1) phosphorylation of Bcl-2 and activation of p33 MBP kinase may play part of the key mechanism for FR-induced apoptosis.
引用
收藏
页码:29 / 38
页数:10
相关论文
共 50 条
  • [32] Effects of histone deacetylase inhibitor FR901228 on the expression level of telomerase reverse transcriptase in oral cancer
    Jun Murakami
    Jun-ichi Asaumi
    Noriko Kawai
    Hidetsugu Tsujigiwa
    Yoshinobu Yanagi
    Hitoshi Nagatsuka
    Tetsuyoshi Inoue
    Susumu Kokeguchi
    Shoji Kawasaki
    Masahiro Kuroda
    Noriaki Tanaka
    Nagahide Matsubara
    Kanji Kishi
    Cancer Chemotherapy and Pharmacology, 2005, 56 : 22 - 28
  • [33] Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report
    Piekarz, RL
    Robey, R
    Sandor, V
    Bakke, S
    Wilson, WH
    Dahmoush, L
    Kingma, DM
    Turner, ML
    Altemus, R
    Bates, SE
    BLOOD, 2001, 98 (09) : 2865 - 2868
  • [34] The histone deacetylase inhibitor depsipeptide (FR901228) enhances the cytotoxic activity of Ad5-TRAIL against prostate and renal tumor cells
    VanOosten, RL
    Moore, JM
    Griffith, TS
    FASEB JOURNAL, 2004, 18 (04): : A62 - A62
  • [35] Phase I trial of the histone deacetylase inhibitor depsipeptide (FR901228) in fludarabine refractory chronic lymphocytic leukemia.
    Bruner, RJ
    Marcucci, G
    Binkley, P
    Xiao, J
    Chan, K
    Parthun, M
    Davis, M
    Fischer, B
    Shank, R
    Moran, M
    Grever, M
    Byrd, JC
    BLOOD, 2002, 100 (11) : 385A - 385A
  • [36] Potential value of the histone deacetylase inhibitor depsipeptide (FR901228) in the treatment of peripheral and cutaneous T-cell lymphoma.
    Piekarz, R
    Robey, R
    Sandor, V
    Fojo, AT
    Bakke, S
    Wilson, W
    Kingma, D
    Turner, M
    Tucker, E
    Bates, SE
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3726S - 3726S
  • [37] Effects of histone deacetylase inhibitor FR901228 on the expression level of telomerase reverse transcriptase in oral cancer
    Murakami, J
    Asaumi, J
    Kawai, N
    Tsujigiwa, H
    Yanagi, Y
    Nagatsuka, H
    Inoue, T
    Kokeguchi, S
    Kawasaki, S
    Kuroda, M
    Tanaka, N
    Matsubara, N
    Kishi, K
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (01) : 22 - 28
  • [38] Depsipeptide (FR901228) induces lysine-specific histone acetylation, differentiation and apoptosis in acute myeloid leukemia cells and demonstrates synergy with decitabine.
    Maghraby, EA
    Murphy, T
    Parthun, MR
    Klisovic, M
    Sklenar, A
    Archer, KJ
    Whitman, S
    Grever, MR
    Caligiuri, MA
    Byrd, JC
    Marcucci, G
    BLOOD, 2001, 98 (11) : 103A - 104A
  • [39] Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells
    Watanabe, T
    Hioki, M
    Fujiwara, T
    Nishizaki, M
    Kagawa, S
    Taki, M
    Kishimoto, H
    Endo, Y
    Urata, Y
    Tanaka, N
    Fujiwara, T
    EXPERIMENTAL CELL RESEARCH, 2006, 312 (03) : 256 - 265
  • [40] Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228
    Kitazono, M
    Goldsmith, ME
    Aikou, T
    Bates, S
    Fojo, T
    CANCER RESEARCH, 2001, 61 (17) : 6328 - 6330